Clinical Trials Browser

Phase 2 × Chondrosarcoma × Immune Checkpoint Inhibitors × Clear all

NCT05193188 2023-02-16

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Phase 2 Recruiting

Chondrosarcoma